VX-710: VRTX began a Phase II open-label trial

Vertex Pharmaceuticals Inc. (VRTX), Cambridge, Mass. Product: VX-710, chemosensitizer combined with doxorubicin Indication: Liver cancer with multidrug resistance Status: VRTX began a Phase II open-la...